"Viking Therapeutics' Breakthrough Weight-Loss Drug Sparks Takeover Speculation"
Viking Therapeutics' stock soared after positive data from its weight-loss drug trial, making the company an attractive takeover target. Analysts raised price targets and reiterated buy ratings, citing the drug's potential to outperform competitors. The company is also developing a treatment for NASH and plans to discuss next steps with the FDA. The stock has gained 392% year-to-date, outperforming the S&P 500.